Locus licenses CRISPR tech to Janssen in potential $818m deal
Press/Media: Press / Media
09/01/2019
Interview on 800 + USD Life Science deal in the CRISPR Antibiotics area
References
Locus licenses CRISPR tech to Janssen in potential $818m deal
Rory O'Neill, 1h
Life Scienes Intellectual Property Review (LSIPR)
https://www.lifesciencesipreview.com/news/locus-licenses-crispr-tech-to-janssen-in-818m-deal-3323
- CRISPR Cas 3, IPR, Antibiotic resistance, Phage therapy
Research areas
ID: 211113141